

BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

March 2020



© 2020 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

BC Centre for Excellence in HIV/AIDS Drug Treatment Program

St. Paul's Hospital 608 - 1081 Burrard Street Vancouver, BC V6Z 1Y6

Tel: 604.806.8515 Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677 St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222 Website: www.cfenet.ubc.ca Email: info@cfenet.ubc.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS







EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS







TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

ABORIGINAL

4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

5. Appendix

5.1 Drug Names and Definitions










March 2020

1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

N = 7398



Health Authority	Male	Female	All	
FRASER	1441	443	1884	
INTERIOR	415	98	513	
NORTHERN	135	88	223	
VANCOUVER COASTAL	3342	446	3788	
VANCOUVER ISLAND	801	157	958	
	6134	1232	7366	
		Unknown/not stated:	32	
		Total:	7398	

Definitions:

On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown




BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





Monthly Report

1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (March 2015 - March 2020)





BRITISH COLUMBIA


in HIV/AIDS

CENTRE for **EXCELLENCE**

HEALTH CARE How you want to be treated.

Ministry of UMBIA Health

Monthly Report



1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (March 2015 - March 2020)

% of Participants




BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS









1.4

(March 2015 - March 2020)

BC-CfE Enrollment: Net Number of New Antiretroviral Participants




in HIV/AIDS

BRITISH COLUMBIA rovidence **CENTRE** for **EXCELLENCE** ALTH CARE ΗE How you want to be treated.



Monthly Report



1.5



Number of Participants

BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS




BRITISH COLUMBIA Ministry of Health

This document is best viewed in colour. Drug definitions available in the back.

BC-CfE Enrollment: New Antiretroviral Participants

Monthly Report




1.6 Percent Distribution of Active Participants by CD4 Count (March 2015 - March 2020)

BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





Monthly Report



1.7 Percent Distribution of Inactive Participants by CD4 Count (March 2015 - March 2020)

Date



% of Participants


BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS






Monthly Report

1.8 Active and Inactive Participants (March 2015 - March 2020)





Monthly Report



1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (March 2015 - March 2020)

E C iii

% of Participants


BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS HEALTH CARE How you want to be treated.



Monthly Report

in HIV/AIDS





BRITISH


COLUMBIA

How you want to be treated.

Drug definitions available in the back.

Monthly Report





Date



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS






This document is best viewed in colour. Drug definitions available in the back.

(March 2015 - March 2020)

Monthly Report



1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (March 2015 - March 2020)



Number of Participants

BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS






Monthly Report



(March 2015 - March 2020)



Date




BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





Monthly Report




1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (March 2015 - March 2020)

BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS HEALTH CARE How you want to be treated.



Monthly Report



1.15

Number of Participants

BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS HEALTH CARE How you want to be treated.



This document is best viewed in colour. Drug definitions available in the back.

Distribution of Participants on Non-Nucleosides


Monthly Report

in HIV/AIDS

How you want to be treated.


COLUMBIA

Health



1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (March 2015 - March 2020)

Monthly Report



1.17



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS






This document is best viewed in colour. Drug definitions available in the back.

Distribution of Participants on Entry/Integrase Inhibitors

Monthly Report



1.18 Baseline CD4 for Antiretroviral First Starts (March 2015 - March 2020)

Date



% of Participants

BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS

BIA CLLENCE HEALTH CARE How you want to be



Ministry of LUMBIA Health

Monthly Report

13,000

12,000

11,000

10,000

9,000

8,000

7,000

6,000

5,000

4,000


3,000

2,000

1,000

0

Number of Participants



2018

1.19 DTP Participants with PVL Measurement within previous five years, and never on ART (March 2015 - March 2020)



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS

2015



2016



2017

Date

This document is best viewed in colour. Drug definitions available in the back.

2020

2019


Monthly Report

CENTRE for **EXCELLENCE**

in HIV/AIDS

HEALTH CARE

How you want to be treated.



Ministry of

Health

BRITISH


COLUMBIA

1.20 Cumulative Resistance Testing Results by Resistance Category (March 2015 - March 2020)

Monthly Report

in HIV/AIDS

% of Participants



BRITISH

COLUMBIA

Health

How you want to be treated.

^{1.21} Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (March 2015 - March 2020)



2.1 Duration of ARV treatment in the Province of BC, 1987-2020 (for HIV+ persons currently on treatment)

Start Year	Duration (years) Median	Male	Female	All		ent CD4 Median		nt PVL Median	Current ARV Median
1987	28	5	0	5	2	580	5	<40	3
1988	29	6	0	6	4	320	6	<40	3
1989	27	53	1	54	37	470	50	<40	3
1990	26	52	1	53	35	540	51	<40	3
1991	26	36	3	39	22	550	37	<40	3
1992	25	63	5	68	41	640	64	<40	3
1993	25	124	16	140	115	560	133	<40	3
1994	23	81	13	94	69	540	90	<40	3
1995	23	132	22	154	117	530	146	<40	3
1996	21	334	53	387	274	565	355	<40	3
1997	19	266	34	300	228	625	285	<40	3
1998	18	194	44	238	177	580	225	<40	3
1999	19	158	37	195	141	580	180	<40	3
2000	19	122	32	154	110	620	142	<40	3
2001	18	116	27	143	109	600	132	<40	3
2002	17	121	27	148	114	585	138	<40	3
2003	16	150	30	180	124	620	169	<40	3
2004	15	156	39	195	152	585	181	<40	3
2005	14	180	45	225	171	620	206	<40	3
2006	13	186	41	227	168	560	204	<40	3
2007	12	248	50	298	221	590	267	<40	3
2008	12	276	69	345	264	630	323	<40	3
2009	11	306	65	371	275	660	342	<40	3
2010	9	275	74	349	253	660	308	<40	3
2011	9	329	74	403	299	700	369	<40	3
2012	8	266	63	329	246	700	300	<40	3
2013	7	267	70	337	239	640	301	<40	3
2014	6	285	52	337	239	720	305	<40	3
2015	5	293	45	338	256	680	309	<40	3
2016	4	280	53	333	242	670	300	<40	3
2017	3	235	36	271	211	670	253	<40	3
2018	2	208	54	262	205	650	248	<40	3

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased **Duration** defined as cumulative years on ARV therapy, excluding periods of treatment interruption **Current CD4 and PVL tests** defined as tests done in the last 6 months (most recent) **Current ARV** defined as number of ARV drugs in the current regimen



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS







2.1 Duration of ARV treatment in the Province of BC, 1987-2020 (for HIV+ persons currently on treatment)

Start Year	Duration (years) Median	Male	Female	All		rent CD4 Median		ent PVL Median	Current ARV Median
2019	1	253	50	303	258	590	291	<40	3
2020	0	78	13	91	79	600	86	87	3
Total:		6134	1238	7372					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased **Duration** defined as cumulative years on ARV therapy, excluding periods of treatment interruption **Current CD4 and PVL tests** defined as tests done in the last 6 months (most recent) **Current ARV** defined as number of ARV drugs in the current regimen



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS







2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2019	7397	788	2456	<40	2145	610
FEB-2019	7377	798	1854	<40	1583	620
MAR-2019	7412	790	2085	<40	1752	610
APR-2019	7366	793	2141	<40	1746	610
MAY-2019	7427	792	2127	<40	1766	620
JUN-2019	7371	803	1926	<40	1594	616
JUL-2019	7381	811	2111	<40	1694	620
AUG-2019	7370	810	2105	<40	1619	600
SEP-2019	7349	806	2012	<40	1566	600
OCT-2019	7404	786	2140	<40	1741	620
NOV-2019	7351	781	2027	<40	1575	630
DEC-2019	7352	777	1700	<40	1279	610
JAN-2020	7368	775	2227	<40	1686	610
FEB-2020	7342	780	1883	<40	1368	628
MAR-2020	7398	770	1630	<40	1122	620

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period) PVL and CD4 tests defined as tests done in the specified month









2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2019	1459	3449	73	73	65	350
FEB-2019	1490	3368	75	108	66	590
MAR-2019	1458	3509	74	636	61	400
APR-2019	1496	3405	81	<50	71	480
MAY-2019	1443	3650	78	87	69	450
JUN-2019	1504	3422	79	<40	71	550
JUL-2019	1492	3497	71	<40	58	530
AUG-2019	1514	3442	82	<40	69	520
SEP-2019	1541	3320	95	<40	78	580
OCT-2019	1481	3625	81	102	69	470
NOV-2019	1501	3575	68	<40	57	560
DEC-2019	1486	3663	58	<40	48	480
JAN-2020	1460	3800	71	255	45	410
FEB-2020	1504	3646	72	<40	55	480
MAR-2020	1461	3827	53	<40	34	530

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs) Days off therapy defined as number of days elapsed since last ARV treatment PVL and CD4 tests defined as tests done in the specified month







Monthly Report

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2019	7364	1459	14	20	191	159	35	13564
FEB-2019	7349	1490	7	16	160	181	-15	13593
MAR-2019	7371	1458	15	13	187	150	22	13613
APR-2019	7326	1496	10	15	152	181	-45	13641
MAY-2019	7390	1443	11	22	197	138	64	13684
JUN-2019	7331	1504	14	13	137	191	-59	13705
JUL-2019	7345	1492	13	13	181	164	14	13728
AUG-2019	7338	1514	12	18	170	177	-7	13764
SEP-2019	7314	1541	14	15	181	201	-24	13791
OCT-2019	7330	1481	3	13	222	148	16	13820
NOV-2019	7324	1501	9	17	164	169	-6	13853
DEC-2019	7322	1486	8	13	165	157	-2	13881
JAN-2020	7340	1460	9	12	181	155	18	13904
FEB-2020	7311	1504	11	19	141	174	-29	13940
MAR-2020	7372	1461	14	22	213	156	61	13975

2.4 BC-CfE Enrollment

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)







Monthly Report

2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2019	55	6803	486	53	7397	0.74%	91.97%	6.57%	0.72%	100.00%
FEB-2019	54	6782	492	49	7377	0.73%	91.93%	6.67%	0.66%	100.00%
MAR-2019	60	6812	490	50	7412	0.81%	91.91%	6.61%	0.67%	100.00%
APR-2019	57	6771	490	48	7366	0.77%	91.92%	6.65%	0.65%	100.00%
MAY-2019	55	6835	492	45	7427	0.74%	92.03%	6.62%	0.61%	100.00%
JUN-2019	57	6785	481	48	7371	0.77%	92.05%	6.53%	0.65%	100.00%
JUL-2019	61	6782	490	48	7381	0.83%	91.88%	6.64%	0.65%	100.00%
AUG-2019	61	6776	483	50	7370	0.83%	91.94%	6.55%	0.68%	100.00%
SEP-2019	57	6754	486	52	7349	0.78%	91.90%	6.61%	0.71%	100.00%
OCT-2019	60	6804	488	52	7404	0.81%	91.90%	6.59%	0.70%	100.00%
NOV-2019	59	6756	486	50	7351	0.80%	91.91%	6.61%	0.68%	100.00%
DEC-2019	61	6765	478	48	7352	0.83%	92.02%	6.50%	0.65%	100.00%
JAN-2020	60	6766	485	57	7368	0.81%	91.83%	6.58%	0.77%	100.00%
FEB-2020	59	6747	476	60	7342	0.80%	91.90%	6.48%	0.82%	100.00%
MAR-2020	61	6800	486	51	7398	0.82%	91.92%	6.57%	0.69%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





Monthly Report

2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

		lamiv	udine			aba	cavir			zidovu	Idine			stavu	udine			didan	osine		te	nofovi	r <taf< th=""><th>></th><th>te</th><th>nofovi</th><th>r <tdi< th=""><th>-></th></tdi<></th></taf<>	>	te	nofovi	r <tdi< th=""><th>-></th></tdi<>	->
	Init	ial	All		Init	ial	All		Initia	al	All		Initi	al	All		Init	al	All		Init	tial	All		Ini	tial	All	
JAN-2019	8	23%	3471 48	8%	7	20%	3258	45%	1	3%	45	1%	0	0%	4	0%	0	0%	1	0%	1	3%	519	7%	26	74%	3358	47%
FEB-2019	13	45%	3463 4	8%	12	41%	3262	45%	0	0%	44	1%	0	0%	1	0%	0	0%	1	0%	3	10%	542	8%	13	45%	3308	46%
MAR-2019	6	30%	3474 48	8%	6	30%	3277	45%	0	0%	43	1%	0	0%	2	0%	0	0%	0	0%	2	10%	559	8%	12	60%	3307	46%
APR-2019	12	43%	3473 4	8%	12	43%	3281	46%	0	0%	43	1%	0	0%	2	0%	0	0%	0	0%	2	7%	586	8%	14	50%	3250	45%
MAY-2019	14	33%	3504 48	8%	14	33%	3312	46%	0	0%	43	1%	0	0%	2	0%	0	0%	1	0%	4	10%	593	8%	24	57%	3264	45%
JUN-2019	3	14%	3484 49	9%	3	14%	3296	46%	0	0%	43	1%	0	0%	2	0%	0	0%	1	0%	2	10%	609	8%	16	76%	3205	45%
JUL-2019	8	36%	3508 49	9%	8	36%	3327	46%	0	0%	39	1%	0	0%	2	0%	0	0%	1	0%	1	5%	625	9%	13	59%	3183	44%
AUG-2019	14	39%	3515 49	9%	12	33%	3340	47%	2	6%	41	1%	0	0%	1	0%	0	0%	1	0%	2	6%	631	9%	20	56%	3145	44%
SEP-2019	5	19%	3497 49	9%	5	19%	3321	46%	0	0%	39	1%	0	0%	1	0%	0	0%	1	0%	5	19%	656	9%	17	63%	3126	44%
OCT-2019	4	14%	3517 49	9%	2	7%	3335	46%	0	0%	38	1%	0	0%	1	0%	0	0%	1	0%	1	4%	671	9%	23	82%	3148	44%
NOV-2019	8	24%	3462 48	8%	7	21%	3285	46%	1	3%	37	1%	0	0%	1	0%	0	0%	1	0%	6	18%	730	10%	19	58%	3115	44%
DEC-2019	1	4%	3442 48	8%	1	4%	3264	46%	0	0%	37	1%	0	0%	1	0%	0	0%	1	0%	14	50%	857	12%	13	46%	3053	43%
JAN-2020	2	9%	3408 4	7%	2	9%	3232	45%	0	0%	34	0%	0	0%	1	0%	0	0%	0	0%	9	39%	1028	14%	12	52%	2964	41%
FEB-2020	3	8%	3360 4	7%	3	8%	3188	45%	0	0%	33	0%	0	0%	1	0%	0	0%	0	0%	16	44%	1173	16%	17	47%	2828	40%
MAR-2020	4	11%	3328 4	6%	4	11%	3163	44%	1	3%	34	0%	0	0%	1	0%	0	0%	0	0%	20	57%	1330	18%	11	31%	2723	38%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS



Monthly Report

2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (continued)

		emtric	itabine	
	Init	tial	All	
JAN-2019	27	77%	3697	51%
FEB-2019	16	55%	3677	51%
MAR-2019	14	70%	3703	51%
APR-2019	16	57%	3666	51%
MAY-2019	28	67%	3693	51%
JUN-2019	18	86%	3651	51%
JUL-2019	14	64%	3656	51%
AUG-2019	22	61%	3628	51%
SEP-2019	22	81%	3630	51%
OCT-2019	24	86%	3672	51%
NOV-2019	25	76%	3675	51%
DEC-2019	27	96%	3717	52%
JAN-2020	21	91%	3768	52%
FEB-2020	33	92%	3788	53%
MAR-2020	30	86%	3863	54%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS



Monthly Report

	fc	osamp	renavi	r		ataza	anavir			daru	navir			lopir	navir			nelfir	navir			riton	avir			saqui	navir	
	Initi	al	All		Init	ial	All		Init	ial	Al		Init	ial	All		Init	al	All		Initi	al	All		Initi	al	All	
JAN-2019	0	0%	6	0%	1	8%	1098	40%	11	92%	1478	54%	0	0%	140	5%	0	0%	0	0%	0	0%	1	0%	0	0%	9	0%
FEB-2019	0	0%	5	0%	2	18%	1070	40%	9	82%	1475	55%	0	0%	138	5%	0	0%	0	0%	0	0%	1	0%	0	0%	9	0%
MAR-2019	0	0%	5	0%	2	40%	1053	39%	3	60%	1487	55%	0	0%	132	5%	0	0%	1	0%	0	0%	1	0%	0	0%	7	0%
APR-2019	0	0%	5	0%	1	10%	1027	39%	7	70%	1478	56%	2	20%	132	5%	0	0%	2	0%	0	0%	1	0%	0	0%	7	0%
MAY-2019	0	0%	5	0%	1	8%	1034	39%	11	92%	1480	56%	0	0%	130	5%	0	0%	2	0%	0	0%	1	0%	0	0%	6	0%
JUN-2019	0	0%	5	0%	0	0%	1003	39%	9	100%	1465	56%	0	0%	120	5%	0	0%	1	0%	0	0%	1	0%	0	0%	6	0%
JUL-2019	0	0%	5	0%	0	0%	982	38%	6	100%	1484	57%	0	0%	113	4%	0	0%	1	0%	0	0%	1	0%	0	0%	6	0%
AUG-2019	0	0%	5	0%	0	0%	969	38%	11	92%	1461	57%	1	8%	112	4%	0	0%	1	0%	0	0%	1	0%	0	0%	5	0%
SEP-2019	0	0%	4	0%	1	8%	955	37%	12	92%	1484	58%	0	0%	110	4%	0	0%	1	0%	0	0%	1	0%	0	0%	6	0%
OCT-2019	0	0%	4	0%	1	7%	959	37%	13	93%	1493	58%	0	0%	109	4%	0	0%	1	0%	0	0%	1	0%	0	0%	6	0%
NOV-2019	0	0%	4	0%	0	0%	941	37%	3	100%	1472	58%	0	0%	101	4%	0	0%	1	0%	0	0%	1	0%	0	0%	6	0%
DEC-2019	0	0%	4	0%	0	0%	924	37%	7	100%	1466	59%	0	0%	100	4%	0	0%	1	0%	0	0%	1	0%	0	0%	6	0%
JAN-2020	0	0%	2	0%	0	0%	912	37%	6	86%	1466	59%	1	14%	97	4%	0	0%	0	0%	0	0%	1	0%	0	0%	6	0%
FEB-2020	0	0%	2	0%	1	11%	874	36%	8	89%	1456	60%	0	0%	97	4%	0	0%	0	0%	0	0%	1	0%	0	0%	6	0%
MAR-2020	0	0%	2	0%	1	10%	861	36%	9	90%	1440	60%	0	0%	94	4%	0	0%	0	0%	0	0%	1	0%	0	0%	6	0%

Ministry of

Health

2.7 Number of Participants on Protease Inhibitor by INGREDIENT

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS



Monthly Report

		tipra	navir	
	Initi	al	All	
JAN-2019	0	0%	1	0%
FEB-2019	0	0%	1	0%
MAR-2019	0	0%	1	0%
APR-2019	0	0%	1	0%
MAY-2019	0	0%	1	0%
JUN-2019	0	0%	1	0%
JUL-2019	0	0%	1	0%
AUG-2019	0	0%	1	0%
SEP-2019	0	0%	1	0%
OCT-2019	0	0%	1	0%
NOV-2019	0	0%	1	0%
DEC-2019	0	0%	1	0%
JAN-2020	0	0%	1	0%
FEB-2020	0	0%	1	0%
MAR-2020	0	0%	1	0%

2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS



HIV/AIDS Drug Treatment Program

Monthly Report

	doravirine			efavirenz			etrav	virine			nevira	apine		rilpivirine						
	Initi	al	All		Initi	ial	All		Init	ial	All		Init	tial	All		Init	ial	All	
JAN-2019	0	0%	0	0%	4	80%	669	35%	0	0%	221	12%	1	20%	695	37%	0	0%	318	17%
FEB-2019	0	0%	0	0%	2	67%	668	35%	1	33%	226	12%	0	0%	683	36%	0	0%	313	17%
MAR-2019	0	0%	0	0%	3	75%	660	35%	0	0%	224	12%	1	25%	681	36%	0	0%	322	17%
APR-2019	0	0%	0	0%	4 1	100%	646	35%	0	0%	223	12%	0	0%	678	36%	0	0%	320	17%
MAY-2019	0	0%	0	0%	6 1	100%	648	35%	0	0%	219	12%	0	0%	672	36%	0	0%	322	17%
JUN-2019	0	0%	0	0%	3	75%	636	35%	0	0%	211	12%	0	0%	664	36%	1	25%	320	18%
JUL-2019	0	0%	1	0%	2 1	100%	635	35%	0	0%	211	12%	0	0%	657	36%	0	0%	322	18%
AUG-2019	0	0%	1	0%	2 1	100%	624	35%	0	0%	207	11%	0	0%	647	36%	0	0%	326	18%
SEP-2019	0	0%	1	0%	4	80%	610	35%	0	0%	209	12%	0	0%	622	35%	1	20%	325	18%
OCT-2019	0	0%	1	0%	6	60%	613	35%	1	10%	211	12%	2	20%	596	34%	1	10%	330	19%
NOV-2019	0	0%	1	0%	5	71%	614	37%	0	0%	209	12%	1	14%	525	31%	1	14%	326	19%
DEC-2019	0	0%	1	0%	3 1	100%	608	37%	0	0%	203	12%	0	0%	513	31%	0	0%	325	20%
JAN-2020	0	0%	1	0%	2 1	100%	589	36%	0	0%	202	12%	0	0%	502	31%	0	0%	325	20%
FEB-2020	0	0%	1	0%	4 1	100%	558	36%	0	0%	198	13%	0	0%	484	31%	0	0%	320	21%
MAR-2020	0	0%	1	0%	4 1	100%	548	36%	0	0%	195	13%	0	0%	466	31%	0	0%	315	21%

2.8 Number of Participants on Non-Nucleosides by INGREDIENT

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Doravirine not currently available on BC-CfE Formulary




BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS



Ministry of

Health



HIV/AIDS Drug Treatment Program

Monthly Report

[bicte	gravir			dolute	egravir			elvite	gravir			mara	viroc		raltegravir			
	Init	ial	All		Init	ial	All		Init	ial	All		Initi	al	All		Init	tial	All	
JAN-2019	0	0%	16	0%	15	75%	2430	63%	4	20%	729	19%	0	0%	39	1%	1	5%	651	17%
FEB-2019	0	0%	27	1%	16	73%	2436	63%	5	23%	726	19%	0	0%	40	1%	1	5%	652	17%
MAR-2019	0	0%	27	1%	8	62%	2482	64%	5	38%	745	19%	0	0%	38	1%	0	0%	647	17%
APR-2019	0	0%	27	1%	8	57%	2496	64%	3	21%	738	19%	0	0%	36	1%	3	21%	636	16%
MAY-2019	0	0%	27	1%	19	68%	2560	64%	6	21%	747	19%	0	0%	37	1%	3	11%	636	16%
JUN-2019	0	0%	27	1%	10	77%	2561	65%	3	23%	744	19%	0	0%	37	1%	0	0%	625	16%
JUL-2019	0	0%	27	1%	13	81%	2607	65%	3	19%	756	19%	0	0%	38	1%	0	0%	628	16%
AUG-2019	0	0%	27	1%	24	86%	2649	65%	1	4%	754	19%	0	0%	36	1%	3	11%	626	15%
SEP-2019	0	0%	28	1%	7	47%	2653	65%	6	40%	756	19%	0	0%	37	1%	2	13%	629	15%
OCT-2019	0	0%	28	1%	13	87%	2723	66%	1	7%	757	18%	0	0%	34	1%	1	7%	630	15%
NOV-2019	3	13%	88	2%	16	70%	2746	65%	4	17%	769	18%	0	0%	33	1%	0	0%	622	15%
DEC-2019	13	65%	231	5%	6	30%	2723	64%	1	5%	743	17%	0	0%	33	1%	0	0%	606	14%
JAN-2020	9	50%	424	10%	7	39%	2693	62%	0	0%	706	16%	0	0%	32	1%	2	11%	595	14%
FEB-2020	14	52%	605	14%	11	41%	2651	60%	2	7%	653	15%	0	0%	29	1%	0	0%	577	13%
MAR-2020	19	70%	757	17%	6	22%	2625	58%	1	4%	622	14%	1	4%	30	1%	0	0%	561	12%

2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS



2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

		sted PI NRTIs		NNRTI NRTIS		egrase NRTIs	Un-boos + 2	ted PI		MDRT		Other
MON-YYYY	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2019	1833	24.78	1481	20.02	3061	41.38	100	1.35	53	0.72	869	11.75
FEB-2019	1804	24.45	1479	20.05	3076	41.70	99	1.34	49	0.66	870	11.79
MAR-2019	1794	24.20	1473	19.87	3126	42.17	98	1.32	50	0.67	871	11.75
APR-2019	1760	23.89	1461	19.83	3139	42.61	100	1.36	48	0.65	858	11.65
MAY-2019	1774	23.89	1450	19.52	3203	43.13	97	1.31	45	0.61	858	11.55
JUN-2019	1742	23.63	1441	19.55	3202	43.44	95	1.29	48	0.65	843	11.44
JUL-2019	1715	23.24	1429	19.36	3240	43.90	92	1.25	48	0.65	857	11.61
AUG-2019	1686	22.88	1403	19.04	3294	44.69	94	1.28	50	0.68	843	11.44
SEP-2019	1699	23.12	1364	18.56	3301	44.92	93	1.27	52	0.71	840	11.43
OCT-2019	1706	23.04	1344	18.15	3362	45.41	93	1.26	52	0.70	847	11.44
NOV-2019	1669	22.70	1274	17.33	3428	46.63	91	1.24	50	0.68	839	11.41
DEC-2019	1644	22.36	1250	17.00	3490	47.47	92	1.25	48	0.65	828	11.26
JAN-2020	1619	21.97	1208	16.40	3570	48.45	87	1.18	57	0.77	827	11.22
FEB-2020	1577	21.48	1153	15.70	3652	49.74	85	1.16	60	0.82	815	11.10
MAR-2020	1547	20.91	1136	15.36	3756	50.77	85	1.15	51	0.69	823	11.12

Definitions:

 ${\bf n}$ is number of participants on the specified regimen class in the specified month % is ratio of n and total number of participants on ART in the specified month



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2019	20	3	3	2	4	6	390
FEB-2019	16	1	0	6	4	4	400
MAR-2019	13	1	2	1	5	4	450
APR-2019	15	3	3	1	2	4	340
MAY-2019	22	1	0	6	8	4	440
JUN-2019	13	2	1	1	2	5	430
JUL-2019	13	1	1	1	3	7	530
AUG-2019	18	0	1	6	4	6	390
SEP-2019	15	0	0	2	4	7	530
OCT-2019	13	1	1	4	4	3	380
NOV-2019	17	4	1	1	1	10	520
DEC-2019	13	0	2	5	2	4	300
JAN-2020	12	0	2	1	4	4	490
FEB-2020	19	5	1	5	3	5	320
MAR-2020	22	4	0	3	1	10	550

Definitions:

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive) **Baseline CD4** is defined as most recent CD4 test before ARV start









2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Partcipants with PVL test, and never on ART	
JAN-2019	12252	3830	
FEB-2019	12260	3829	
MAR-2019	12290	3859	
APR-2019	12317	3883	
MAY-2019	12333	3884	
JUN-2019	12333	3889	
JUL-2019	12350	3904	
AUG-2019	12382	3921	
SEP-2019	12401	3939	
OCT-2019	12435	3963	
NOV-2019	12457	3972	
DEC-2019	12481	3986	
JAN-2020	12544	4039	
FEB-2020	12589	4069	
MAR-2020	12595	4065	

Definitions:

Patients with PVL test are defined as having at leat one PVL test within previous five years, and not reported deceased/moved Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month










3.1 **Distribution of HIV/AIDS Drug Treatment Program Active Participants** March 2020



BY HEALTH SERVICES DELIVERY AREA

CENTRE for **EXCELLENCE** in HIV/AIDS




Ministry of BRITISH COLUMBIA Health

N = 7398


3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participants March 2020


INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participants March 2020

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA








BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS



BRITISH COLUMBIA Ministry of Health


3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants March 2020

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants March 2020


VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



Distribution of HIV/AIDS Drug Treatment Program Active Participants 3.6

March 2020





How you want to be treated.

Health

4.1 Distribution of Participants in BC-CfE Registries by Age and Gender INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST	20-34	7	7	*
KOOTENAY	35-49	9	10	*
	50+	27	39	*
	Total HSDA:	43	56	28
KOOTENAY	0-19	*	*	*
BOUNDARY	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	74	98	55
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	364	495	282
THOMPSON/CARIBOO/	0-19	*	*	0
SHUSWAP	20-34	*	*	14
	35-49	*	*	52
	50+	*	*	82
	Total HSDA:	195	268	148
Total HA:		676	917	513
			Ever	Currently
	Age Group	Alive	treated with ARVs	treated with ARVs
	0-19	5	5	*
	20-34	59	60	*
	35-49	180	201	*
	50+	432	651	*
Total HA:		676	917	513
			Ever	Currently
Gender		Alive	treated with ARVs	treated with ARVs
Male		540	732	415
Female		136	185	98
Currently treated with AR	Vs	# of patients	Med Age	Med CD4 Med PVL
Total HA:		513	55	600 35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month Med CD4 and PVL tests defined as most recent tests (as of specified month)



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

Total HA:	,	676	513
	<5 years	131	105
	5 years or more	144	118
	10 years or more	401	290
	Treatment Duration	Alive	Currently treated with ARVs
Total HA:		676	513
	Total HSDA:	195	148
	<5 years	40	28
SHUSWAP	5 years or more	46	39
THOMPSON/CARIBOO/	10 years or more	109	81
	Total HSDA:	364	282
	<5 years	65	56
	5 years or more	72	61
OKANAGAN	10 years or more	227	165
	Total HSDA:	74	55
	<5 years	13	11
BOUNDARY	5 years or more	15	11
KOOTENAY	10 years or more	46	33
	Total HSDA:	43	28
	<5 years	13	10
KOOTENAY	5 years or more	11	7
EAST	10 years or more	19	11
HSDA	Duration	Alive	treated with ARVs
	Treatment		Currently

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month **Treatment Duration** defined as number of years since ARV initiation



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS







4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicans ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicans currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	46	64	16	26
KOOTENAY BOUNDARY	76	124	27	47
OKANAGAN	226	929	60	285
THOMPSON/CARIBOO/SHUSWAR	D 138	517	38	141
Total:	486	1634	141	499

HSDA of	# of Patients seeking Physician's care	
Patient Residency	out of HA	
EAST KOOTENAY	*	
KOOTENAY BOUNDARY	*	
OKANAGAN	*	
THOMPSON/CARIBOO/SHUS	SWAP *	
Total:	94	

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months **# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs	
FRASER EAST	0-19	6	6	6	
	20-34	33	35	25	
	35-49	98	108	73	
	50+	240	315	189	
	Total HSDA:	377	464	293	
FRASER NORTH	0-19	7	7	*	
	20-34	116	116	*	
	35-49	345	373	*	
	50+	574	903	*	
	Total HSDA:	1042	1399	790	
FRASER SOUTH	0-19	6	6	5	
	20-34	112	114	85	
	35-49	329	375	266	
	50+	553	814	445	
	Total HSDA:	1000	1309	801	
Total HA:	•	2419	3172	1884	
			Ever	Currently	
	Age Group	Alive	treated with ARVs	treated with ARVs	
	0-19	19	19	13	
	20-34	261	265	187	
	35-49	772	856	602	
	50+	1367	2032	1082	
Total HA:		2419	3172	1884	
			Ever	Currently	
Gender		Alive	treated with ARVs	treated with ARVs	
Male		1835	2430	1441	
Female		584	742	443	
Currently treated with AR	Vs	# of patients	Med Age	Med CD4 Med PVL	_
Total HA:		1884	52	630 35	

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month Med CD4 and PVL tests defined as most recent tests (as of specified month)



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS







4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration FRASER Health Authority

	Treatment		Currently
HSDA	Duration	Alive	treated with ARVs
FRASER EAST	10 years or more	226	177
	5 years or more	72	56
	<5 years	79	60
	Total HSDA:	377	293
FRASER NORTH	10 years or more	587	424
	5 years or more	249	195
	<5 years	206	171
	Total HSDA:	1042	790
FRASER SOUTH	10 years or more	567	447
	5 years or more	223	169
	<5 years	210	185
	Total HSDA:	1000	801
Total HA:	l.	2419	1884
	Treatment		Currently
	Duration	Alive	treated with ARVs
	10 years or more	1380	1048
	5 years or more	544	420
	<5 years	495	416
Total HA:		2419	1884

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month **Treatment Duration** defined as number of years since ARV initiation









4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries FRASER Health Authority

HSDA of Physician Residency	# of Physicans ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicans currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	145	494	29	49
FRASER NORTH	256	1579	49	233
FRASER SOUTH	223	1492	49	460
Total:	624	3565	127	742

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA	
FRASER EAST	203	
FRASER NORTH	649	
FRASER SOUTH	493	
Total:	1345	

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





4.7 Distribution of Participants in BC-CfE Registries by Age and Gender VANCOUVER COASTAL Health Authority

		Alive	Ever treated with ARVs	Currently treated with ARVs
HSDA	Age Group	Alive		
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	*
CUAST GARIBALDI	20-34	*	*	*
	35-49	*		*
	50+		*	
	Total HSDA:	345	495	295
RICHMOND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	176	225	136
VANCOUVER	0-19	23	23	7
	20-34	450	465	312
	35-49	1371	1543	972
	50+	2841	4866	2066
	Total HSDA:	4685	6897	3357
Total HA:		5206	7617	3788
			Ever	Currently
	Age Group	Alive	treated with ARVs	treated with ARVs
	0-19	27	27	9
	20-34	507	523	359
	35-49	1495	1679	1070
	50+	3177	5388	2350
Total HA:		5206	7617	3788
			Ever	Currently
Gender		Alive	treated with ARVs	treated with ARVs
Unknown		2	2	0
Male		4602	6694	3342
Female		602	921	446
Currently treated with AR	RVs	# of patients	Med Age	Med CD4 Med PVL
Total HA:		3788	53	640 35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month Med CD4 and PVL tests defined as most recent tests (as of specified month)



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS







4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER COASTAL Health Authority

	Treatment		Currently
HSDA	Duration	Alive	treated with ARVs
NORTH SHORE/	10 years or more	190	156
COAST GARIBALDI	5 years or more	90	77
	<5 years	65	62
	Total HSDA:	345	295
RICHMOND	10 years or more	101	72
	5 years or more	37	30
	<5 years	38	34
	Total HSDA:	176	136
VANCOUVER	10 years or more	2828	1933
	5 years or more	1107	804
	<5 years	750	620
	Total HSDA:	4685	3357
Total HA:	L	5206	3788
	Treatment		Currently
	Duration	Alive	treated with ARVs
	10 years or more	3119	2161
	5 years or more	1234	911
	<5 years	853	716
Total HA:		5206	3788

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month **Treatment Duration** defined as number of years since ARV initiation









4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries VANCOUVER COASTAL Health Authority

HSDA of Physician Residency	# of Physicans ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicans currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBAL	DI 183	501	60	172
RICHMOND	44	289	12	93
VANCOUVER	642	10934	219	5255
Total:	869	11724	291	5520

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA	
NORTH SHORE/COAST	GARIBALDI *	
RICHMOND	*	
VANCOUVER	*	
Total:	120	

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months **# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





4.10 Distribution of Participants in BC-CfE Registries by Age and Gender VANCOUVER ISLAND Health Authority

			Ever	Currently	
HSDA	Age Group	Alive	treated with ARVs	treated with ARVs	
CENTRAL	0-19	*	*	*	
VANCOUVER	20-34	*	*	*	
ISLAND	35-49	*	*	*	
	50+	*	*	*	
	Total HSDA:	335	470	276	
NORTH	0-19	*	*	*	
VANCOUVER	20-34	*	*	*	
ISLAND	35-49	*	*	*	
	50+	*	*	*	
	Total HSDA:	127	169	107	
SOUTH	0-19	*	*	0	
VANCOUVER	20-34	*	*	57	
ISLAND	35-49	*	*	148	
	50+	*	*	370	
	Total HSDA:	751	1059	575	
Total HA:		1213	1698	958	
			Ever	Currently	
	Age Group	Alive	treated with ARVs	treated with ARVs	
	0-19	*	*	*	
	20-34	*	*	*	
	35-49	*	*	*	
	50+	*	*	*	
Total HA:		1213	1698	958	
			Ever	Currently	
Gender		Alive	treated with ARVs	treated with ARVs	
Male		1004	1402	801	
Female		209	296	157	
Currently treated with AR	Vs	# of patients	Med Age	Med CD4 Med P	VL
Total HA:		. 958	54	570 3	-

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month Med CD4 and PVL tests defined as most recent tests (as of specified month)



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

	Treatment		Currently
HSDA	Duration	Alive	treated with ARVs
CENTRAL	10 years or more	183	151
	5 years or more	76	62
ISLAND	<5 years	76	63
	Total HSDA:	335	276
NORTH	10 years or more	72	61
VANCOUVER	5 years or more	35	29
ISLAND	<5 years	20	17
	Total HSDA:	127	107
SOUTH	10 years or more	437	308
VANCOUVER	5 years or more	160	139
ISLAND	<5 years	154	128
	Total HSDA:	751	575
Total HA:		1213	958
	Treatment		Currently
	Duration	Alive	treated with ARVs
	10 years or more	692	520
	5 years or more	271	230
	<5 years	250	208
Total HA:	-	1213	958

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month **Treatment Duration** defined as number of years since ARV initiation









4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries VANCOUVER ISLAND Health Authority

HSDA of Physician Residency	# of Physicans ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicans currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	204	872	82	201
NORTH VANCOUVER ISLAND	151	268	50	79
SOUTH VANCOUVER ISLAND	219	1809	46	572
Total:	574	2949	178	852

HSDA of	# of Patients seeking Physician's care	
Patient Residency	out of HA	
CENTRAL VANCOUVER ISLA	ND 52	
NORTH VANCOUVER ISLAN	D 40	
SOUTH VANCOUVER ISLANI	D 111	
Total:	203	

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





4.13 Distribution of Participants in BC-CfE Registries by Age and Gender NORTHERN Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs	
NORTH EAST	0-19	*	*	*	
	20-34	*	*	*	
	35-49	*	*	*	
	50+	*	*	*	
	Total HSDA:	40	48	23	
NORTH WEST	20-34	11	12	8	
	35-49	16	32	14	
	50+	41	64	34	
	Total HSDA:	68	108	56	
NORTHERN INTERIOR	0-19	5	5	*	
	20-34	23	24	*	
	35-49	71	90	*	
	50+	90	153	*	
	Total HSDA:	189	272	144	
Total HA:		297	428	223	
			Ever	Currently	
	Age Group	Alive	treated with ARVs	treated with ARVs	
	0-19	6	6	*	
	20-34	36	38	*	
	35-49	106	144	*	
	50+	149	240	*	
Total HA:		297	428	223	
			Ever	Currently	
Gender		Alive	treated with ARVs	treated with ARVs	
Male		179	263	135	
Female		118	165	88	
Currently treated with AR	Vs	# of patients	Med Age	Med CD4 Med PV	L
Total HA:		223	50	540 35	

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month Med CD4 and PVL tests defined as most recent tests (as of specified month)









4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration NORTHERN Health Authority

	Treatment		Currently
HSDA	Duration	Alive	treated with ARVs
NORTH EAST	10 years or more	21	*
	5 years or more	13	*
	<5 years	6	*
	Total HSDA:	40	23
NORTH WEST	10 years or more	34	26
	5 years or more	22	19
	<5 years	12	11
	Total HSDA:	68	56
NORTHERN INTERIOR	10 years or more	78	57
	5 years or more	61	52
	<5 years	50	35
	Total HSDA:	189	144
Total HA:		297	223
	Treatment		Currently
	Duration	Alive	treated with ARVs
	10 years or more	133	94
	5 years or more	96	80
	<5 years	68	49
Total HA:		297	223

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month **Treatment Duration** defined as number of years since ARV initiation









4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries NORTHERN Health Authority

HSDA of Physician Residency	# of Physicans ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicans currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	43	64	8	9
NORTH WEST	82	164	18	34
NORTHERN INTERIOR	117	471	20	188
Total:	242	699	46	231

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA	
NORTH EAST	7	
NORTH WEST	19	
NORTHERN INTERIOR	12	
Total:	38	

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





			Ever	Currently
HA	HSDA	Alive	treated with ARVs	treated with ARVs
INTERIOR	EAST KOOTENAY	6	10	*
	KOOTENAY BOUNDARY	6	9	treated with ARVs * * * 44 31 45 54 130 24 6 382 412 43 17 34
	OKANAGAN	23	39	*
	THOMPSON/CARIBOO/SHUSWAP	26	47	*
	Total HA:	61	105	44
FRASER	FRASER EAST	38	48	31
	FRASER NORTH	54	90	45
	FRASER SOUTH	78	111	54
	Total HA:	170	249	130
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	25	48	24
	RICHMOND	8	13	6
	VANCOUVER	483	859	382
	Total HA:	516	920	412
VANCOUVER	CENTRAL VANCOUVER ISLAND	52	81	43
ISLAND	NORTH VANCOUVER ISLAND	19	28	130 24 6 382 412 43 17
	SOUTH VANCOUVER ISLAND	40	84	34
	Total HA:	111	193	94
NORTHERN	NORTH EAST	11	13	8
	NORTH WEST	26	57	24
	NORTHERN INTERIOR	72	111	61
	Total HA:	109	181	93
Total:		967	1648	773

4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

Gender	Alive	Ever treated with ARVs	Currently treated with AR	√s
Male	608	1052	487	
Female	359	596	286	
Currently treated with ARVs	# of patients	Med Age	Med CD4 Med PV	L
Total:	773	52	480 35	

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month Med CD4 and PVL tests defined as most recent tests (as of specified month)



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





5.1 Drug Names and Definitions

Abacavir (Ziagen, ABC): a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Amphotericin B (Fungilin): a drug used for treatment of candidiasis and other fungal infections.

Amprenavir (Agenerase, APV): a PROTEASE INHIBITOR from ViiV Healthcare. No longer marketed in Canada.

Antiretroviral (ARV): a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz, ATV): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla (ATP): the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Bictegravir: an INTEGRASE INHIBITOR from Gilead Sciences.

Boosted PI: a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Cobicistat: a pharmacokinetic enhancer ("booster") given with other antiretrovirals to improve drug exposure. Cobistat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

Combination Therapy: initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Combivir (CBV): the ViiV Healthcare trade name for a tablet containing both ZIDOVUDINE and LAMIVUDINE.

Complera (CPL): the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

Darunavir (Prezista, DRV): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatmentexperienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.







Descovy (DSC): the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

Didanosine (Videx, DDI): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Dolutegravir (Tivicay, DTG): an INTEGRASE INHIBITOR from ViiV Healthcare.

Doravirine: a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Merck.

Efavirenz (Sustiva, Auro efavirenz, EFV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir (EGV): an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

Emtricitabine (FTC): a NUCLEOSIDE ANALOG from Gilead Sciences. It its currently available as a component of TRUVADA and other combinations.

Enfuvirtide (Fuzeon, T20): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (Intelence, ETV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Ethambutol (Myambutol): an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir, fAPV): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Genvoya (GNV): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

Granulocyte Colony Stimulating Factor (GCSF, Neupogen): a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa (KIV): the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

Lamivudine (3TC): a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra, LPV/r): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS







Monthly Report

Maraviroc (Celsentri, MVC): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.

MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

Moxifloxacin: a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept, NFV): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune, NVP): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

NRTI: see NUCLEOSIDE ANALOG.

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are preactivated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Octreotide Acetate (Sandostatin): a drug used to treat chronic refractory diarrhea.

Odefsey (ODF): the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Paromomycin (Humatin): an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS





Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

PI: see PROTEASE INHIBITOR.

Prezcobix (PZC): the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

Raltegravir (RGV, Isentress): an INTEGRASE INHIBITOR from Merck.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant, RPV): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir, RTV): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure ("booster").

Saquinavir (Invirase, SQV): a PROTEASE INHIBITOR from Hoffman-La Roche.

Stavudine (Zerit, d4T): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild (STR): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

Tenofovir alafenamide (Tenofovir AF, TAF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus, TPV): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq (TRQ): the ViiV Healthcare's trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir (TRZ): the ViiV Healthcare's trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada (TRU): the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.









Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir, AZT): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.



BRITISH COLUMBIA CENTRE for EXCELLENCE in HIV/AIDS



